Woodcock Warns of ‘Excessive Worship Of The RCT,’ Pushes New Drug Approval Pathway

 
• By Sarah Karlin-Smith
  
close up of person praying
Janet Woodcock said excessive focus on randomized controlled trials prevents openness to other avenues for regulatory approval. (Shutterstock)

More from Rare Diseases

More from R&D